"To start the preparation process for an end of Phase 2 meeting with the FDA"
I think this is PTN's next major event after this statement 11/8/2012
"---Carl Spana, Ph.D., President and CEO of Palatin. "Our next steps are to continue to compile and analyze additional data, to start the preparation process for an end-of-Phase 2 meeting with the FDA, and to further our discussions with potential collaboration partners."
Later in the same press release company management said they would try to start a Phase 3 study in the second half of 2013.
Yani made an incredibly stupid statement.about how PTN would have to raise cash if there is no partnership. I guess we can expect that sort of snide comment from someone who paid $20 for their stock.There is no phase 3 until PTN has a partner. Key to closing the collaboration agreement, is a successful meeting with the FDA. There will be upfront money, milestone payments and royalties. The partner will pay all expenses for two phase 3 studies that will be run at the same time.
Dum-de-dum-de-dum. At last Phil goes negative. No partner no PTN says Phil, because they can't move forward without a partner. That's good news confirms Langley BS service- a buy signal. With friends like Phil, let's hope PTN doesn't have enemies!
Note to Phil- this is not insulting, it is ridicule.
If PTN raised money now they would also be able to tell a potential partner that they have the cash to go it alone, putting them in a stronger bargaining position with a potential partner, heightening the chances of getting a better deal.
PTN could well be thinking of raising cash here and now.
There may or may not be a partner. Don't be so naive as to believe everything the Vice-President of Palatin tells you off the record.
As for paying for all expenses for two simultaneous Phase 3 studies, I think that would be too risky.
Would not count on a partner doing that, again, no matter what the PTN VP told you.
"Phase 3 activities" could just mean designing the study, who knows.
"Based on the results of discussions with the FDA and external advisors regarding the results of this trial and further development steps, Phase 3 activities are anticipated to start in the second-half of calendar year 2013."